Kymera Therapeutics
KYMR • NASDAQ
Kymera Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Nello Mainolfi, with a market cap of $6.9B.
CEONello Mainolfi
Next Earnings
Upcoming earnings announcement for Kymera Therapeutics
Date
Friday, May 8, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.87
Revenue Estimate
$9.5M
Earnings History
Past 12 earnings reports for Kymera Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | -$0.97Est: -$0.78 | -24.4% | $2.9MEst: $16.2M | -82.3% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.90Est: -$0.76 | -18.4% | $2.8MEst: $24.5M | -88.7% | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.95Est: -$0.77 | -23.4% | $11.5MEst: $28.3M | -59.4% | 10-Q |
| May 9, 2025 | Q1 2025 | -$0.82Est: -$0.91 | +9.9% | $22.1MEst: $10.7M | +106.0% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.88Est: -$0.79 | -11.4% | $7.4MEst: $14.8M | -50.1% | 10-K |
| Oct 31, 2024 | Q3 2024 | -$0.82Est: -$0.84 | +2.4% | $3.7MEst: $10.4M | -63.9% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.58Est: -$0.68 | +14.7% | $25.7MEst: $12.6M | +104.4% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.69Est: -$0.73 | +5.5% | $10.3MEst: $13.7M | -24.9% | 10-Q |
| Feb 22, 2024 | Q4 2023 | -$0.25Est: -$0.40 | +37.5% | $47.9MEst: $42.0M | +14.1% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.90Est: -$0.72 | -25.0% | $4.7MEst: $16.0M | -70.4% | — |
| Aug 3, 2023 | Q2 2023 | -$0.67Est: -$0.71 | +5.6% | $16.5MEst: $14.1M | +17.4% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.70Est: -$0.68 | -2.9% | $9.5MEst: $14.2M | -33.1% | — |